Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L
Open Access
- 9 November 2016
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 26 (5) , 1163-1176
Abstract
Purpose It has been argued that generic health-related quality of life measures are not sensitive to certain disease-specific improvements; condition-specific preference-based measures may offer a better alternative. This paper assesses the validity, responsiveness and sensitivity of a cancer-specific preference-based measure, the EORTC-8D, relative to the EQ-5D-3L. Methods A longitudinal prospective population-based cancer genomic cohort, Cancer 2015, was utilised in the analysis. EQ-5D-3L and the EORTC QLQ-C30 (which gives EORTC-8D values) were asked at baseline (diagnosis) and at various follow-up points (3 months, 6 months, 12 months). Baseline values were assessed for convergent validity, ceiling effects, agreement and sensitivity. Quality-adjusted life-years (QALYs) were estimated and similarly assessed. Multivariate regression analyses were employed to understand the determinants of the difference in QALYs. Results Complete case analysis of 1678 patients found that the EQ-5D-3L values at baseline were significantly lower than the EORTC-8D values (0.748 vs 0.829, p < 0.001). While the correlation between the instruments was high, agreement between the instruments was poor. The baseline health state values using both instruments were found to be sensitive to a number of patient and disease characteristics, and discrimination between disease states was found to be similar. Mean generic QALYs (estimated using the EQ-5D-3L) were significantly lower than condition-specific QALYs (estimated using the EORTC-8D) (0.860 vs 0.909, p < 0.001). The discriminatory power of both QALYs was similar. Conclusions When comparing a generic and condition-specific preference-based instrument, divergences are apparent in both baseline health state values and in the estimated QALYs over time for cancer patients. The variability in sensitivity between the baseline values and the QALY estimations means researchers and decision makers are advised to be cautious if using the instruments interchangeably.Keywords
Funding Information
- Victorian Cancer Agency (Translational Research Program)
This publication has 55 references indexed in Scilit:
- Validation of the International Prostate Symptom Score in Chinese males and females with lower urinary tract symptomsHealth and Quality of Life Outcomes, 2014
- Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic painHealth and Quality of Life Outcomes, 2013
- Changes in self-reported and parent-reported health-related quality of life in overweight children and adolescents participating in an outpatient training: findings from a 12-month follow-up studyHealth and Quality of Life Outcomes, 2013
- A comparison of four different approaches to measuring health utility in depressed patientsHealth and Quality of Life Outcomes, 2013
- Using QALYs in CancerPharmacoEconomics, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational studyQuality of Life Research, 2010
- A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measuresThe European Journal of Health Economics, 2009
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986